Trials / Terminated
TerminatedNCT05113342
Descartes-25 in Relapsed/Refractory Multiple Myeloma
Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Cartesian Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refractory Multiple Myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Descartes-25 | allogeneic Mesenchymal Stem Cell product. |
Timeline
- Start date
- 2021-11-25
- Primary completion
- 2023-05-09
- Completion
- 2024-11-08
- First posted
- 2021-11-09
- Last updated
- 2024-11-12
Locations
3 sites across 2 countries: United States, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05113342. Inclusion in this directory is not an endorsement.